⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
Living with a Rare Disease: A Pastor’s Journey Finding the Right Care and Treatment for NF1-PN
globenewswire.com
SWKS
MRK
Monoclonal Antibodies (mAbs) for Oncology Global Report 2026: A $228 Billion Market by 2030, Driven by Technological Advances, New Product Launches, Label Expansions, Increasing Prevalence
globenewswire.com
MRK
KEYTRUDA ® (pembrolizumab) Plus WELIREG ® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
businesswire.com
MRK
WELIREG ® (belzutifan) Plus LENVIMA ® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
businesswire.com
MRK
A Symbol of Crisis: As Colorectal Cancer Deaths Rise, Fight CRC Installs United in Blue on the National Mall
globenewswire.com
AMGN
BMY
EXEL
EXAS
GENK
GSK
JNJ
MRK
NTRA
PFE
KEYTRUDA ® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
businesswire.com
MRK
KEYTRUDA ® (pembrolizumab) Plus Padcev ® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
businesswire.com
MRK
Head and Neck Cancer Therapeutics Market to Reach USD 2.6 Billion by 2032, Driven by Immunotherapy and Precision Oncology - Credence Research Inc.
prnewswire.com
MRK
BMY
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
businesswire.com
MRK
Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris
businesswire.com
MRK